2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.
Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.
The biggest cohort of patients with prostate cancer has not led to the discovery of biomarkers for advanced disease. Primary metastatic tumors need to be studied in more detail to determine the evolution of this disease.
It would also be interesting to identify markers of progression for patients with advanced disease within primary tumors by comparing the genomic alterations across lesions.
Related Content: